Haematologica Reports 2006; 2(issue 3): 37-38[prev][index][next]

Zoledronic acid impairs mammary carcinogenesis in BALB/c mice transgenic
for the Her-2/neu oncogene
Coscia M,¹ Quaglino E,² Curcio C,² Pantaleoni F,¹ Forni G,² Massaia M,^1
1Division of Hematology, Department of Medicine and Experimental Oncology,
Laboratory of Hematology Oncology, Center for Experimental Research and Medical Studies, San Giovanni Battista Hospital, University of Turin, Torino, Italy; ²Department of Clinical and Biological Sciences, S. Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin

Zoledronic acids (Zol) is the most potent aminobisphosphonate clinically available.¹ Preclinical in vivo data suggest that it modulates the development of bone disease, decreases tumor burden² with a direct anti-cancer activity,^3-5 and reduces the migration and the metastatic invasion of cancer cells.⁶
[>Read full article in PDF]